The overall goal of this SPORE in lung cancer proposal is to translate recent advances in the understanding of the molecular pathogenesis of lung cancer into new methods to prevent, diagnose, and treat lung cancer. This SPORE is a logical development of the planning P20 SPORE in Lung Cancer awarded 3 years ago to UTSW. It developed out of 32 years of planning effort between UT Southwestern Medical Center (UTSW) and M.D. Anderson Cancer Center (MDACC), bringing together two major complementary strengths in lung cancer research in the areas of prevention, molecular pathogenesis, early detection, and development of novel therapies based on translational research. This SPORE consists of 5 inter-related projects and 3 supporting Cores. The projects in Lung Cancer are: 1. Identification of 3p Recessive Oncogenes; 2. Genetic Susceptibility: 3. Molecular Early Detection; 4. Chemoprevention in Former Smoker; 5. Mutant p53 Epitope Targeting. The Cores are: A. Administrative; B. Pathology and Tissue Resource; and C. Informatics. All of the scientific projects are: a) translational in nature; b) focus on human lung cancer; c) arose out of conjoint planning between UTSW and MDACC and involve investigators from both institutions as Co- investigators; d) interact with other projects; e) include basic and clinical investigators; and f) utilize Core resources. There is a substantial plan for innovative Developmental Projects, and a plan for Career Development that has already been productive from the UTSW P20 planning SPORE effort. There is a heavy emphasis on prevention, early detection and the development of novel therapies that could be applied to very early stage disease. In addition, the Developmental Program includes a project for the testing for genetic predisposition to nicotine dependency as a new approach to identifying persons at high risk of developing lung cancer. Achievement of the aims and objectives of this proposal will result in a major decrease in the incidence, morbidity and mortality of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA070907-03
Application #
2769857
Study Section
Special Emphasis Panel (SRC (08))
Program Officer
Ujhazy, Peter
Project Start
1996-09-30
Project End
1999-08-31
Budget Start
1998-09-01
Budget End
1999-08-31
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Pietanza, M Catherine; Waqar, Saiama N; Krug, Lee M et al. (2018) Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36:2386-2394
Abrams, Zachary B; Zucker, Mark; Wang, Min et al. (2018) Thirty biologically interpretable clusters of transcription factors distinguish cancer type. BMC Genomics 19:738
Tanaka, Ichidai; Sato, Mitsuo; Kato, Toshio et al. (2018) eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci 109:1843-1852
Huang, Fang; Ni, Min; Chalishazar, Milind D et al. (2018) Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. Cell Metab 28:369-382.e5
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Pozo, Karine; Minna, John D; Johnson, Jane E (2018) Identifying a missing lineage driver in a subset of lung neuroendocrine tumors. Genes Dev 32:865-867
Fan, C-W; Yarravarapu, N; Shi, H et al. (2018) A synthetic combinatorial approach to disabling deviant Hedgehog signaling. Sci Rep 8:1133
Cascone, Tina; McKenzie, Jodi A; Mbofung, Rina M et al. (2018) Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab 27:977-987.e4
Cascone, Tina; Gold, Kathryn A; Swisher, Stephen G et al. (2018) Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg 105:418-424
Ng, Patrick Kwok-Shing; Li, Jun; Jeong, Kang Jin et al. (2018) Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell 33:450-462.e10

Showing the most recent 10 out of 1059 publications